Pumosetrag Hydrochloride
Pumosetrag hydrochloride had been in phase II clinical trials for the treatment of gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS). This compound was originally discovered by Mitsubishi Tanabe Pharma, then licensed to Dynogen (now Edusa Pharmaceuticals) in 2004. However, all researches on this drug candidate were discontinued.
General Information
Update Date：2015-11-11
- Drug Name：
- Pumosetrag Hydrochloride
- Research Code：
- DDP-733; MKC-733
- Trade Name：
- MOA：
- 5-HT3 agonist
- Indication：
- Gastroesophageal reflux disease (GERD); Irritable bowel syndrome (IBS)
- Status：
- Phase II (Discontinued)
- Company：
- Mitsubishi Tanabe (Originator) , Edusa
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-11-11
|
Molecular Weight | 339.84 | ||||||||||||
| Formula | C15H17N3O2S • HCl | |||||||||||||
| CAS No. |
153062-94-3 (Pumosetrag); 194093-42-0 (MKC 773); |
|||||||||||||
| Chemical Name | Thieno[3,2-b]pyridine-6-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4,7-dihydro-7-oxo-, hydrochloride (1:1) | |||||||||||||
| Pumosetrag （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||